Seattle, Washington, USA (March 27, 2025 PT): Shin Nippon Biomedical Laboratories, Ltd. (TSE Prime: 2395, Representative Chairman, President & CEO: Ryoichi Nagata, M.D., Ph.D.; hereinafter "SNBL") ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback